BSBE(SZ:300406) Xin Lang Cai Jing·2025-11-21 01:27Core Insights - The stock price of Jiukang Bio remained unchanged on November 20, with a trading volume of 32.39 million yuan [1] - The company experienced a financing net purchase of 776,100 yuan on the same day, indicating low financing activity compared to historical levels [1] Financing and Margin Trading - On November 20, Jiukang Bio had a financing purchase of 5.29 million yuan, with a total financing balance of 169 million yuan, representing 2.15% of its market capitalization [1] - The financing balance is below the 30th percentile of the past year, indicating a low level of financing [1] - In terms of margin trading, there were no shares repaid, but 700 shares were sold short, amounting to 9,366 yuan at the closing price [1] - The short selling balance stood at 115,740 yuan, which is above the 80th percentile of the past year, indicating a high level of short selling [1] Financial Performance - For the period from January to September 2025, Jiukang Bio reported a revenue of 1.012 billion yuan, a year-on-year decrease of 18.24% [2] - The net profit attributable to shareholders was 272 million yuan, down 27.03% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Jiukang Bio's shareholders was 18,100, a decrease of 2.48% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.54% to 23,502 shares [2] - Cumulatively, Jiukang Bio has distributed 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.3446 million shares, a decrease of 1.4085 million shares from the previous period [3]